Clinical Trial Update: Managed Access Programs for AIN457, Secukinumab

View source ↗

Summary

Clinical trial update describing managed access programs for AIN457 (secukinumab) for hidradenitis suppurativa; the program status is AVAILABLE.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa (HS) | Status: AVAILABLE